Swiss drugmaker Roche has abandoned global diverse workforce targets and compatriot Novartis is ending its use of diverse ...

FRANKFURT (Reuters) -Swiss drugmaker Roche has abandoned global targets for a more diverse workforce to avoid penalties from ...

Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...

Acne creams from retailers including Walgreens, La Roche-Posay and Proactiv have been voluntarily recalled due to elevated ...

Roche Holding (ROCH:CA) now has a Canadian dollar hedged Canadian Depositary Receipt, but it currently lacks liquidity. Read ...

Roche’s up to $1 billion investment will provide access to Oxford BioTherapeutics’ antibody-drug conjugate platform for ...

Roche, which put billions on the line a year ago across several ADC pacts, kicked off 2025 by returning to Innovent Biologics ...

Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to ...

Kepler Capital analyst David Evans maintained a Buy rating on Roche Holding AG (RHHVF – Research Report) on March 21 and set a price target of ...

The inquiry is the latest effort by the European Commission and European countries to scrutinize potential antitrust behavior ...

Angesichts des Drucks der Trump-Regierung hat der Schweizer Pharmariese Roche seine seit langem bestehenden globalen ...

Meanwhile, fellow Swiss company Novartis will no longer use diverse panels in its hiring process for U.S.-based employees, ...